Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:10:10.100Z.
Consensus retrieved: 2026-10-06T16:52:12.359Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:10:10.100Z.
Quote observation: 2026-10-06T18:01:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 42c577abd9d5aa4e94c21ca47db030ff1e5598993d2f9cb9fa7ffb886cc2a8f3
Forward PE Ratio (N/A) = Dated Quote Price ($2.15) / Consensus Forward EPS ($-3.32)
FORWARD PE RATIO
N/A
Xenetic Biosciences, Inc.
Market Cap
$4.94M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | $4.94M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.90M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.03M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.04M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.81M | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.71M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.21M | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.23M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.15, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.32 | $-3.32 – $-3.32 | 1 | n/m |
| 2027-12-31 | $-0.34 | $-0.34 – $-0.34 | 1 | n/m |
| 2028-12-31 | $-0.23 | $-0.23 – $-0.23 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
